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Abstract  
 
Objectives: To determine whether IOTA diagnostic models developed for pre-
operative diagnosis of ovarian cancer could also be used to differentiate 
between benign and malignant adnexal tumours in the population of women 
attending gynaecology outpatient clinics.  
 
Methods: All women referred to our outpatient clinic were first examined by a 
Level II ultrasound operator.  In those diagnosed with adnexal tumours the 
IOTA LR1/2 protocol was used to evaluate the masses. The LR1 and LR2 
models were then used to assess the risk of malignancy.  Subsequently women 
were also examined by a Level 3 examiner who used pattern recognition to 
differentiate between benign and malignant tumours. Women with an 
ultrasound diagnosis of malignancy were offered surgery whilst asymptomatic 
women with presumed benign lesions were offered conservative management 
with a minimum follow-up of 12 months. The initial diagnosis was compared 
with two reference standards: histological findings and/or a comparative 
assessment of tumour morphology on follow-up ultrasound scans. All women in 
whom tumour classification on follow-up changed from benign to malignant 
were offered surgery. 
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Results: 489 women who had either or both of the reference standards were 
included into the final analysis. Their mean age was 50 years (range 16-91) and 
45% of them were menopausal.  342/489 (69.9%) women had surgery and 
147/489 (30.1%) were managed conservatively. The malignancy rate was 
137/489 (28.0%). Overall sensitivities of LR1 and LR2 for the diagnosis of 
malignancy were 97.1% (95% CI: 92.7-99.2) and 94.9% (95%CI: 89.8-97.9) and 
specificities were 77.3% (95%CI: 72.5-81.5) and 76.7% (95%CI; 71.9-81.0) 
respectively (p>0.05).   In comparison to pattern recognition [Sensitivity 94.2% 
(95% CI: 88.8 to 97.4); specificity 96.3% (95% CI: 93.8 to 98.0)], the 
specificities of IOTA models were significantly lower. (p < 0.0001) A significantly 
higher number of women would have been offered surgery for suspected 
cancer if women were assessed using the IOTA models instead of pattern 
recognition [213/489 (43.6%) versus 142/489 (29.0%)] (p<0.001). 
 
Conclusions: IOTA models maintained their high sensitivity when used in the 
outpatient setting.  Specificity was relatively low which indicates that a 
significant proportion of women would have been offered unnecessary surgery 
for suspected ovarian cancer.  These findings show that IOTA models could be 
used as a first stage test to diagnose ovarian cancer in the outpatient setting 
but a different second stage test is required to minimise the number of false 
positive findings. 
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Introduction  
The International Ovarian Tumour Analysis (IOTA) group developed two logistic 
regression models (LR1&LR2), aiming to improve the accuracy of pre-operative 
ultrasound diagnosis of ovarian cancer diagnosis by non-expert operators of 
average ability and experience. 1-3  
A number of previous original and validation studies showed that LR1 and LR2 
perform well in the hands of expert operators and can facilitate pre-operative 
differentiation between benign and malignant tumours in women undergoing 
surgical treatment of adnexal tumours.1, 4 Only a minority of women with an 
ultrasound diagnosis of an adnexal tumour however, require surgery and in the 
routine clinical practice the critical issue is not who will perform surgery but 
whether an intervention is required at all. There have been no studies so far, 
which assessed the suitability of IOTA models for the diagnosis of ovarian 
cancer in outpatient setting and for prioritising women with adnexal tumours for 
surgical interventions. The prevalence of malignancy in women attending 
outpatient clinics in likely to be lower, which could result in a larger number of 
interventions in women with benign disease even if the good diagnostic 
accuracy of IOTA models is maintained. 
 
Another difficulty with using a test in the outpatient setting is that only a 
proportion of women would be selected for surgical treatment. Histological 
findings, which are traditionally used as the reference standard for assessing 
the accuracy of models for the diagnosis of ovarian cancer, are not applicable 
to population of women managed conservatively. In such circumstances 
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“delayed type prospective cross sectional studies” which include carefully 
planned and prolonged clinical follow up may provide the best evidence 
required to define the appropriate reference standard.5 In the context of ovarian 
cancer diagnosis, it remains uncertain what is the required length of follow up 
and appropriate frequency of visits to determine the nature of an adnexal 
tumour. 
 
In this prospective study we assessed the accuracy of IOTA LR1/LR2 models 
for the diagnosis of ovarian cancer in outpatient settings using histology as the 
first reference standard and the comparative assessment of tumour morphology 
on follow-up ultrasound scans as a second reference test.  We also assessed 
the potential impact on the intervention rates of a policy, which would replace 
pattern recognition with the IOTA models for prioritising women with adnexal 
tumours for surgery 
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Methods 
This was a single centre prospective observational study of consecutive women 
attending our gynaecological diagnostic unit for a variety of gynaecological 
complaints. We also included women who were diagnosed with ovarian cyst on 
previous imaging organised in  primary care and were referred to us for 
specialist gynaecological imaging and management advice. The patients were 
recruited for the study between May 2009 to January 2012 and all women 
completed follow-up by January 2014. During the initial recruitment visit a 
detailed history was taken and women underwent clinical and ultrasound 
examinations. Women over the age of 40 who had no periods for 12 
consecutive months with no other identifiable physiological, pathological or 
medical cause were defined as post-menopausal. Women who were over the 
age of 50 years and had had a hysterectomy were also classified as being 
postmenopausal.  
 
All ultrasound examinations were performed by NN who was a Level II operator. 
She was trained in use of the IOTA protocol 1,6 but not in tumour “pattern 
recognition”. 7-10 She was discouraged from attempting to designate a 
histological diagnosis or attempt to differentiate subjectively between benign 
and malignant tumours on ultrasound scan. Women with evidence of adnexal 
tumours on ultrasound scan were considered suitable for this study, but those 
with unilocular, anechoic cysts less than 2cm were excluded.  Pregnant women 
and those unable to undergo a transvaginal scan were also excluded from the 
final data analysis. 
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The probability of malignancy within an adnexal mass was estimated by using 
the IOTA Logistic Regression Model (LR1 and LR2). Twelve variables were 
used for the LR1 calculation (1) personal history of ovarian cancer (yes=1, 
no=0): (2) current use of hormonal therapy (yes=1, no=0): (3) age of the patient 
(years): (4) maximum diameter of lesion (mm): (5) evidence of pain during the 
examination of the mass (yes=1, no=0): (6) presence of ascites (yes=1, no=0): 
(7) presence of blood flow within a solid papillary projection (yes=1, no=0): (8) 
purely solid tumour: (9) maximum diameter of the largest solid component 
(expressed in millimetres, but with no increase > 50 mm): (10) irregular internal 
cyst walls (yes=1, no=0): (11) presence of acoustic shadows (yes=1, no=0): 
(12) colour score (1-4 where 1 is no flow and 4 is maximum flow). The 
probability of malignancy was calculated using the formula y = 1/ (1 + exp[-z]), 
where z = – 6.7468 +1.5985 (1) – 0.9983 (2) + 0.0326 (3) + 0.00841 (4) – 
0.8577 (5) + 1.5513 (6) + 1.1737 (7) + 0.9281 (8) + 0.0496 (9) + 1.1421 (10) – 
2.3550 (11) + 0.4916 (12) as described in the original IOTA study.  The 
probability y is dichotomised at a score of 0.1 to give a predictive diagnosis of 
cancer. 
 
LR2 was calculated based on 6 of the above variables: (3), (6), (7), (9), (10) and 
(11). The formula to determine the probability of malignancy was y = 1/ (1 + 
exp[-z]), where z = - 5.3718 + 0.0354 (3) + 1.6159 (6) + 1.1768 (7) + 0.0697 (9) 
+ 0.9586 (10) - 2.9486 (11) and as with LR1 the probability y is dichotomised at 
a score of 0.1 to give a predictive diagnosis of cancer. 
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The Level II operator recorded the IOTA assessments in the research file and 
these assessments were not available to the clinicians who made decisions 
about the patients’ plan of care. In cases of multiple lesions, the lesions which 
were more likely to be malignant according to the IOTA model score, were 
included into the analysis, as the diagnosis of malignancy in one lesion 
supersedes the diagnosis of any coexisting benign lesions. Following the 
examination by the Level II operator, the women with adnexal tumours were re-
examined independently by an expert ultrasound operator (DJ) who used 
subjective pattern recognition to determine the nature of the adnexal tumour. 
Women with suspected ovarian cancer following the expert exam were referred 
to our gynaecological oncology team for further management.  Women with 
presumed benign lesions were offered choice between conservative 
management and surgery taking into account their clinical symptoms and 
personal preferences. 
 
Women who opted for conservative management were offered regular follow up 
ultrasound scans starting with 6 monthly intervals for a minimum of 12 months. 
Women who become symptomatic during follow-up and those who requested 
intervention were offered surgery. In those who remained asymptomatic, follow-
up ultrasound findings were compared to the initial diagnosis. Surgery was 
offered to all women in whom tumour classification was changed from benign to 
malignant on any of the follow-up ultrasound scans. Only when the data 
collection was completed at the end of the study, were the IOTA LR1 and LR2 
calculations of the risk of malignancy performed and included in the data 
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collection sheets. Histopathology was the primary reference standard used. 
Tumours were classified according to the World Health Organisation (WHO) 
guidelines and malignancies were staged according to the International 
Federation of Gynecology and Obstetrics criteria.11-12 For the women in whom 
surgery was not required, an ultrasound scan at 12 months or more after the 
primary scan confirming the initial diagnosis of benign lesion was used as the 
second reference standard.                                                                                                              
 
It was determined by the local Research and Development Department that 
formal ethical assessment and approval was not required as the steps in the 
conduct of the study were routine practice in the unit. This includes 
morphological analysis of the tumours using the IOTA examination technique, 
measurement technique and terminology for the assessment of adnexal 
masses which are also a part of our standard clinical practice. In addition to this, 
therapeutic decisions were not based on the IOTA model scores.  
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Statistical analysis 
 
The sample size for this study was determined using Harrell’s recommendation 
that a validation dataset should contain at least 100 “events”, that is borderline 
or malignant tumours.13 Our validation dataset has 137 events, therefore it 
satisfies this requirement. 
 
Initially, the data was analysed after assuming that both reference tests had 
perfect (100%) sensitivity and specificity.  The sensitivity, specificity and overall 
accuracy of the three diagnostic tests (LR1, LR2 and pattern recognition) were 
calculated under this assumption and presented with exact 95% confidence 
intervals.  Formal comparisons across different index tests were made using 
McNemar’s test; the exact version of this test was used when necessary.  
These analyses were performed in the software package Stata 14.0 © (Stata 
Corp., College Station, TX, USA). 
 
A secondary analysis was performed using a Bayesian approach similar to that 
of de Groot. 14 This analysis was performed to reduce the bias that may occur if 
the results of the alternative reference standard (follow-up ultrasound) are 
treated identically to the results from the preferred reference standard 
(histology) when the former may be of lower quality. In detail we created a 
probabilistic model that relates the underlying (unknown) status of the patient to 
the results of the corresponding reference test.  This model assumes that the 
choice of reference test (histology or follow-up ultrasound) was related to the 
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underlying status of the patient (that is, patients with cancer were more likely to 
be assessed using histology).  In addition, we assumed that the histology 
results were always correct whereas the ultrasound results were imperfect.  Our 
(prior) belief was that the sensitivity and specificity of ultrasound were both 
probably close to 90% and almost certainly within the range 80-100%.  Low 
information priors were used for all other parameters.  OpenBUGS was used to 
estimate (posterior) distributions for the model parameters including patient 
status and the sensitivities and specificities of follow-up ultrasound and the 
three diagnostic tests.15 All results are presented as medians with 95% credible 
intervals.  To check the robustness of our results, additional analyses were run 
where the prior beliefs for ultrasound performance were changed to reflect 
worse performance. 
Results 
 
A total of 555 consecutive women attended for ultrasound assessment during 
the study period.  11 women were pregnant and they were excluded from the 
data analysis. A flow chart showing eligibility of women for the study and 
summary of their management is shown in Fig. 1. (Fig. 1)  A total of 342/544 
(62.9%) women had surgery after their first or a subsequent ultrasound scan 
while 147/544 (27.0%) were managed conservatively. (Table 1) 41/544 (7.5%) 
were lost to follow up, 13 women died soon after the diagnosis of adnexal 
tumour was made and one woman received chemotherapy as the primary 
treatment for presumed metastatic bowel cancer. Among the 13 women who 
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died, 5 had a non-ovarian malignancy (oesophageal (2), pancreatic, cervical 
and endometrial), 4 had non-malignant medical conditions (amyloidosis, chronic 
renal failure and bronchiectasis, dementia with urinary sepsis and alcoholic 
induced liver failure) and 4 had suspected ovarian malignancies. The patients 
ranged from 16 to 91 years of age with a mean age of 50 years.  237/544 
(43.6%) of women were post-menopausal.  
 
After excluding the 55/544 (10.1%) women who had neither reference test, the 
final diagnosis of a malignant tumour was made in 137/489 (28.0%) women and 
benign tumours were diagnosed in the remaining 352 (72.0%) women. 
Histological diagnosis was available in 342 women and they are shown in 
Table2. Majority of malignant tumours were invasive 116/137(84.7%) whilst the 
remaining 21/137 (15.3) were borderline. All borderline tumours were Stage I, 
whilst among invasive tumours) there were 26/116 (22.4%) Stage I, 
5/116(4.3%) Stage II, 37/116(31.9%) Stage III and 22/116 (22.4%) were Stage 
IV tumours.  The most common indications for surgery were suspected ovarian 
cancer (n=152 [44.4%]) and pelvic pain (n=75 [21.9%]). Other indications were 
the woman’s choice (n=62 [18.1%]), part of subfertility or urological surgery 
(n=35 [10.2%]) and other reasons such as pressure symptoms, UKCTOCS 
Screening positive, prophylactic surgery or change in appearance of tumour on 
follow up (n=18 [5.3%]).   Only 8 tumours increased in size during follow up 
whilst the remaining 139 (94.6%) were the same size, smaller or completely 
resolved. (Table 3) In these 8 women the cyst increased in size between 21% 
and 94% but none of the women had surgery for that reason. In women 
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managed expectantly the median time for their follow-up ultrasound scan was 
14.5 months (12 to 68 months maximum).  
 
Using pattern recognition as the primary diagnostic test, 148 women were 
diagnosed with cancer. The management of women in respect of the predicted 
nature of pelvic tumour is shown in Table 4. The predicted diagnoses of the 
nature of the adnexal tumours at the initial visit using PR, LR1 and LR2 are 
shown in Table 5. There were significant differences in the proportion of women 
diagnosed with malignancy between PR and LR1/LR2. (P<0.0001) (Table 6) 
Assuming that the rate of intervention would be identical in women diagnosed 
with cancer and benign disease regardless of the diagnostic method used, 
there would also be a significant increase in the number of women having 
surgery for presumed malignancy if IOTA models were used instead of PR to 
assess women for interventions. (P< 0.0001) This is because the false positive 
rate for LR1/LR2 was significantly higher that of pattern recognition. The overall 
intervention rates including both benign and malignant lesions for PR, LR 1 and 
LR2, however would not be significantly different. (P>0.05) (Table 5) 
 
 
There were 10 patients who had surgery after completing 12 months follow up 
which enabled a comparison of the two reference standards. In one of them 
there were discordant results for histology and the follow-up ultrasound scan. 
These results; however, suggest a good level of agreement between histology 
and the follow up visit strategy. The woman with the discordant results had 
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surgery because her tumour had changed morphologically. Histology result 
however was benign polypoid endometriosis.  
 
The primary analysis was performed assuming that both reference tests 
(histology and follow up ultrasound scans) had the same perfect accuracy.  
(Table 7) This showed LR1, LR2 and pattern recognition all demonstrated high 
sensitivities, but there were significant differences in the specificities for the 
diagnosis of ovarian cancer between PR and the IOTA models when tests were 
used at the initial visit. When assuming differing accuracy for histology (100%) 
and follow up ultrasound scans (90%), the results were similar to when both 
reference tests were assumed to be 100% accurate. (Table 8) 
 
There were eight women with cancer (borderline [5] and invasive [3]) who were 
misdiagnosed as benign disease using pattern recognition (8/137; 5.8% [95% 
CI: 2.6% to 11.2%]). Among the invasive malignancies, all were stage 1 with 
two dermoid tumours with early malignant transformation within and the one 
seromucinous adenocarcinoma. This caused delayed intervention in only one 
woman who was eventually diagnosed with a borderline tumour. Using LR1 
there would have been four false negative cancer diagnoses (borderline [2] and 
invasive [2])  (2.9% [95%CI: 0.8% to 7.3%]) (P = 0.13 when compared to PR) 
diagnoses compared to seven (borderline [3] and invasive [4]) (5.1% [95%CI: 
2.1% to 10.2%]) using LR2 (P=1.0 when compared to PR) neither of which was 
statistically significant. The tumours missed by LR1/LR2 were those missed by 
PR except for 1 metastatic tumour detected by PR and missed by LR1. 
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Discussion  
 
Our study has shown that accuracy of LR1/LR2 for the diagnosis of ovarian 
cancer in the outpatient setting was similar to the previous studies, which were 
carried out pre-operatively. However, if LR1/LR2 had been used as the primary 
diagnostic test to guide the management decisions, rather than the pattern 
recognition, a significantly higher proportion of women would have been 
referred for treatment by gynaecological oncologists because of suspected 
ovarian cancer.  
 
In previous original and subsequent validation studies the IOTA logistic 
regression models provided accurate diagnosis of ovarian cancer both in hands 
of expert and non-expert operators.1,4,16-18 The models; however, had always 
been used in population of women who all had surgery. In view of that the 
results could be affected by selection bias and they cannot be extrapolated to 
low risk population majority of whom do not require surgical intervention.  The 
results of previous studies can therefore only be used to help to select a 
surgeon (general or oncological) who should do the operation or the route of the 
surgery (laparoscopic or open). 19 A more relevant question in clinical practice; 
however, is whether surgery is required at all for the woman where symptoms, 
fertility or her wishes do not indicate surgery is required. 
 
A difficulty in conducting studies on populations of women with adnexal tumours 
who are managed conservatively is the lack of agreement on the reference 
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standard to define the nature of the lesion. In women with presumed benign 
lesions the only way to rule out an ovarian cancer in the absence of histological 
diagnosis is by arranging follow up visits for a certain length of time. The natural 
history of ovarian cancer is unknown and the decisions and about the length 
and frequency of follow visits are pragmatic and based on consensus of 
opinions, rather than science. Most ovarian cancer screening projects adopted 
the policy of six-monthly or annual visits in women with normal ultrasound 
findings, which is deemed to be sufficiently frequent to detect early disease 
before spreading beyond the ovaries. 20 All women in our study had detectable 
lesions at the time of the initial scan. We therefore postulated that under these 
circumstance a 12 month follow up should be long enough to detect changes in 
the appearance and size of adnexal tumours which would be suggestive of their 
malignant nature.  The absence of such changes was our second reference 
standard to discriminate between benign and malignant lesions.   
 
During follow-up, it is possible that some women could develop new 
abnormalities.  This may erroneously be classified as a prior misdiagnosis 
rather than the new disease that it is. However, in some women, it should be 
possible to identify two separate lesions which may overcome this limitation in a 
proportion of cases. 
 
All the women in the study were assessed by at least one of the reference 
standards: histology and/or a follow-up ultrasound scan in12 months or more.  
This helped us to reduce the incomplete verification bias of including only 
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surgical patients. Bias may though still arise if the results of the alternative 
reference standard are treated identically to the results from the preferred 
reference standard when they may not be identical. This is because the two 
reference standards may be of different quality and it is possible that follow up 
ultrasound scans would be less than 100% accurate when compared to 
histology (preferred reference test). This information was taken into account 
when performing the statistical analysis, but in our study the results were not 
different when the presumed accuracy of ultrasound follow up (alternative test) 
was reduced to 90%. 14   
 
Our results showed that in this population with a 28.0% malignancy rate the 
LR1 and LR2 models had a high sensitivity and a moderate specificity to 
diagnose ovarian cancer. The specificity of LR1 and LR2 models were 
significant lower than pattern recognition (P < 0.0001) whilst the sensitivity was 
not significantly different (P=0.13 [LR1]). This relatively high false positive rate 
of LR1 would theoretically result in 62% more women being treated for potential 
ovarian cancer. However, the four women with false negative diagnoses of 
ovarian cancer (one invasive epithelial and three borderline) would have 
received earlier treatment.  
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Strengths – 
This study assessed and corrected for the potential bias of analysing only the 
women who had surgery. This is the first study on LR1/LR2 to do this. 
 
Limitations –  
The overall intervention rate in our study was relatively high which reflects the 
nature of work in a large clinical centre.  Many women are referred following the 
diagnosis of adnexal cyst in primary or community care. They often have larger 
lesions and are advised by their GPs that surgery is required even in the lesions 
are considered to be benign. The diagnostic strategy described in this study is 
appropriate for specialists making decisions about surgery. Further work is 
required to assess the suitability of the IOTA models to assist general 
practitioners and Level I operators in deciding who should be referred to 
specialist centres for further assessment.  
 
In addition, 10% of women who were all diagnosed with benign tumours on 
pattern recognition did not complete follow up. There were no missed 
malignancies in 147 women with complete follow up data who were also 
managed expectantly. In view of that it is unlikely that the comparison of 
performance of IOTA models with pattern recognition would have been 
significantly different had all the women completed the study. 
 
Further studies are required to assess the performance of IOTA models in 
hands of Level II sonographers receiving direct referrals from primary care and 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
reproductive health care physicians where the risk of ovarian cancer would be 
lower and the proportion of complex tumours difficult to classify on ultrasound 
would be less than in our population.  
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Figure Legend 
Figure 1 Flowchart of study participants and their management 
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Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Flowchart of study participants and their management.  
Deceased (N=13) 
Chemotherapy (N=1) 
Planned surgical management
(N=343) 
Planned expectant management 
(N=187) 
Lost to follow up
(N=41) 
Changed to surgery
(N=16) 
Changed to expectant 
(N=17) 
Non-pregnant women with ultrasound
diagnosis of adnexal tumour (N=544) 
Completed surgical management
(N=342) 
Completed expectant management 
(N=147) 
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Table 1: Final Reference Standard Allocation in 544 non-pregnant women included 
into the study.  
 
Reference Standard N(%) 
Histology Only 
Follow-up USS Only 
Both 
Neither 
332 (61.0) 
147 (27.0) 
10 (1.8) 
55 (10.1) 
Total 544 (100) 
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Table 2: Histological diagnoses (N=342).  
 
 
  Histology 
N (%) 
Benign  
n=205  
(59.9%) 
Cystadenoma (n=43) /Cystadenofibroma (n=14) 
Endometrioma 
Mature cystic teratoma (Dermoid) 
Benign functional (haemorrhagic cyst, follicular 
cyst) 
Fibroma 
Normal adnexa at surgery 
Torsion (Functional x3, Cystadenofibroma, 
Fibroma) 
Pedunculated Leiomyoma 
Pelvic Inflammatory Disease 
Fibrothecoma 
Hydrosalpinx 
Pseudocyst 
Brenner 
Actinomycosis 
Struma Ovarii 
Myolipoma 
57 (27.8) 
47 (22.9) 
31 (15.1) 
29 (14.1) 
10 (4.9) 
5 (2.4) 
5 (2.4) 
4 (2.0) 
4 (2.0) 
3 (1.5) 
3 (1.5) 
2 (1.0) 
2 (1.0) 
1 (0.5) 
1 (0.5) 
1 (0.5) 
   
Malignant 
n=137 
(40.1%) 
 
 
Invasive epithelial 
Borderline (serous, mucinous, endometroid) 
Invasive non-epithelial 
Metastases, Recurrence, Unknown 
 
 
     84(61.3) 
21(15.3) 
4 (2.9) 
28(20.4) 
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Table 3: Morphological appearances of expectantly managed adnexal tumours on 
follow up scans (N = 147).  
 
Follow up findings N (%) 
Resolved 
Smaller*  
Unchanged 
Larger* 
34 (23.1) 
21 (14.3) 
84 (57.1) 
8 (5.4) 
Total 147 (100) 
*>20% change in the mean diameter 
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Table 4: Summary of management in respect to the predicted nature of adnexal 
tumour (N=544) 
 
Management Benign (N=396) Malignant (N=148) 
Surgery (N,%) 200 (50.5) 142 (95.9) 
Chemotherapy (N,%) - 1 (0.7) 
Expectant (N,%) 147 (37.1) - 
Deceased (N,%) 9 (2.3) 4(2.7) 
Lost to follow up (N,%) 40 (10.1) 1 (0.7) 
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Table 5: Proportion of women with ultrasound diagnosis of malignancy using pattern 
recognition, LR1 and LR2 and associated true and estimated*# intervention rates (N 
= 489). 
 
 
 Malignant 
Diagnosis 
n 
Intervention rates 
for Malignant 
Diagnoses  
n (%) 
Intervention rates 
for All Diagnoses 
n (%) 
Pattern 
Recognition 
142 142/489 (29.0%) 342/489 (69.9%) 
LR1 213 213/489  (43.6%)* 372/489 (76.1%)# 
LR2 212 212/489  (43.4%)* 372/489 (76.1%)# 
*Malignant diagnosis: Assumption that in keeping with pattern recognition all women with a malignant 
diagnosis using LR1 and LR2 would have had surgery. 
#
Benign Diagnosis: Assumption that in keeping with PR where 200/347 (57.6%) with benign 
diagnoses had surgery, the same proportion of women with benign diagnoses by LR1 and LR2 would 
also have had surgery.  
#
LR1 rate = (213 + 57.6% of 276)/489 = 76.1% 
#
LR2 rate = (212 + 57.6% of 277)/489 = 76.1% 
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Table 6: A comparison between LR1 and Pattern Recognition in classifying the 
tumours as benign or malignant (n = 489) 
 
REF = Benign  PR 
  Benign Malign 
LR1 Benign 271 1 
Malign 68 12 
P < 0.0001 
REF = Malignant  PR 
  Benign Malign 
LR1 Benign 4 0 
Malign 4 129 
P = 0.13 (Exact) 
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Table 7: Primary analysis using both reference standards (N = 489, malignancy rate 
137/489 (28.0%) 
 
 
 Sensitivity 
(%, 95% CI) 
Specificity 
(%, 95% CI) 
ROC area* 
(95% CI) 
Diagnostic OR 
(95% CI) 
PR 94.2 
(88.8 to 97.4) 
96.3 
(93.8 to 98.0) 
0.952 
(0.930 to 0.974) 
420 
(172 to 1027) 
LR1 97.1 
(92.7 to 99.2) 
77.3 
(72.5 to 81.5) 
0.872 
(0.846 to 0.898) 
113 
(42.1 to 303) 
LR2 94.9 
(89.8 to 97.9) 
76.7 
(71.9 to 81.0) 
0.858 
(0.829 to 0.887) 
61.1 
(27.9 to 134) 
* Based on single cutpoint 
Both reference standards are assumed to have perfect performance of 100% 
accuracy. 
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Table 8: Secondary Bayesian analysis assuming ‘high’ diagnostic performance of 
follow up ultrasound (90% accuracy) (N = 489, malignancy rate 137/489 (28.0%)  
 
 
 Sensitivity 
(%, 95% CrI*) 
Specificity 
(%, 95% CrI) 
ROC area** 
(95% CrI) 
Diagnostic OR 
(95% CrI) 
PR 93.8 
(88.9 to 97.0) 
96.4 
(94.1 to 98.0) 
0.948 
(0.923 to 0.968) 
430  
(169 to 971) 
LR1 96.7 
(92.8 to 98.8) 
77.5 
(73.0 to 81.5) 
0.868 
(0.840 to 0.894) 
116 
(42.1 to 297) 
LR2 94.5 
(89.8 to 97.6) 
76.8 
(72.3 to 81.0) 
0.854 
(0.823 to 0.882) 
61.1 
(27.4 to 128) 
*CrI = credible interval. 
** Based on single cutpoint 
Follow-up scan reference standard assumed to have 90% accuracy compared to 
histology reference standard assumed to have 100% accuracy. 
Two Markov Chain Monte Carlo (MCMC) chains of 3000 samples were run in 
OpenBUGS with the first 1000 of each discarded as the burn-in period. 
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